HIV drug combination for increasing barrier against resistance
US12005072B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2019 |
| Grant date | Jun 11, 2024 |
| Priority date | — |
| Expiry date | Mar 9, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant invention relates to a method for reducing the risk for development of anti-viral treatment resistance due to an HIV mutation in a human subject infected with HIV, comprising administering EFdA in combination with one or more anti-viral agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.